Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.

The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. A double-blind 12-week evaluation suggested comparable efficacy between 1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 equally divided doses. A lower incidence of side effects was noted in the oxaprozin group. An open 6-month study substantiated the efficacy and safety of oxaprozin.
AuthorsW J Reynolds, S F Shaar, A Buik, W J Lancee
JournalThe Journal of rheumatology (J Rheumatol) 1979 May-Jun Vol. 6 Issue 3 Pg. 345-50 ISSN: 0315-162X [Print] CANADA
PMID385873 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Oxazoles
  • Propionates
  • Aspirin
  • Arthritis, Rheumatoid (drug therapy)
  • Aspirin (administration & dosage, therapeutic use)
  • Chemical Phenomena
  • Chemistry
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Evaluation
  • Humans
  • Oxazoles (administration & dosage, therapeutic use)
  • Propionates (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: